Organic models of flavoenzymes consist of a binding site covalently attached to a flavin derivative acting as the catalytic site. The earlier reported synthesis of such a model using alpha-cyclodextrin as the binding site proved to be difficult to reproduce with beta-cyclodextrin. The synthetic strategy involved attaching a fully constructed riboflavin onto a cyclodextrin by a nucleophilic reaction. Riboflavin was found to decompose under the reaction conditions. A new method for the synthesis of flavocyclodextrins involving construction of the flavin moiety onto cyclodextrin is convenient and can be used to synthesize 6-flavocyclodextrins and 2-flavocyclodextrins.
Organic models of flavoenzymes consist of a binding site covalently attached to a flavin derivative acting as the catalytic site. The earlier reported synthesis of such a model using alpha-cyclodextrin as the binding site proved to be difficult to reproduce with beta-cyclodextrin. The synthetic strategy involved attaching a fully constructed riboflavin onto a cyclodextrin by a nucleophilic reaction. Riboflavin was found to decompose under the reaction conditions. A new method for the synthesis of flavocyclodextrins involving construction of the flavin moiety onto cyclodextrin is convenient and can be used to synthesize 6-flavocyclodextrins and 2-flavocyclodextrins.
The reaction of carbonyl compounds with 2-mercaptoethanol to prepare 1,3-oxathiolanes has been successfully carried out in ionic liquids using ytterbium(III) triflate as a catalyst. Yields of the products are high and the catalyst can be easily recovered and reused in this reaction.
Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
公开号:US20040209865A1
公开(公告)日:2004-10-21
The present invention relates to alkyne compounds of general formula I
1
wherein the groups and residues A, B, W, X, Y, Z, R
1
and R
2
have the meanings given in claim
1
. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
[DE] NEUE ALKIN-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER WIRKUNG UND DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL<br/>[EN] NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES ALKINE A ACTIVITE ANTAGONISTE CONTRE MCH ET MEDICAMENTS CONTENANT CES COMPOSES
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2004039780A1
公开(公告)日:2004-05-13
Die vorliegende Erfindung betrifft Alkin-Verbindungen der allgemeinen Formel (I), in der die Gruppen und Reste A, B, W, X, Y, Z, R1 und R2 die in Anspruch 1 angegebenen Bedeutungen aufweisen. Ferner betrifft die Erfindung Arzneimittel enthaltend mindestens ein erfindungsgemäßes Alkin. Auf Grund der MCH-Rezeptor antagonistischen Aktivität eignen sich die erfindungsgemäßen Arzneimittel zur Behandlung von metabolischen Störungen und/oder Essstörungen, insbesondere von Obesitas, Bulimie, Anorexie, Hyperphagia und Diabetes.
Metalloporphyrin and heteropoly acid catalyzed oxidation of CNOH bonds in an ionic liquid: biomimetic models of nitric oxide synthase
作者:Nidhi Jain、Anil Kumar、Shive M.S. Chauhan
DOI:10.1016/j.tetlet.2005.02.088
日期:2005.4
Water soluble iron(III) porphyrins and phosphotungstic acid in an ionic liquid are effective catalysts for the H2O2 mediated oxidation of the CNOH bond in N-hydroxyarginine and other oximes. The carbonyl compounds generated as the oxidation products can be easily isolated from the reaction media. These systems serve as biomimetic models of nitric oxide synthase (NOS) and the catalyst immobilized in
离子液体中的水溶性铁(III)卟啉和磷钨酸是有效的催化剂,可用于H 2 O 2介导的N-羟基精氨酸和其他肟中CNOH键的氧化。可以容易地从反应介质中分离出作为氧化产物而生成的羰基化合物。这些系统可作为一氧化氮合酶(NOS)的仿生模型,固定在离子液体中的催化剂可以轻松回收和再利用。